Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects ≥ 42 days to ≤ 64 days of age.~2. Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements~Exclusion Criteria:~1. Subjects whose parents or legal guardians are unwilling or unable to give written informed consent to participate in the study.~2. History of previous immunization with a vaccine containing any of the 5 antigen components of investigational vaccine.~3. History of anaphylactic shock(immediate hypersensitivity reactions), urticaria or other allergic reactions after previous vaccination or known hypersensitivity to any vaccine component.~4. Administration of parenteral immunoglobulin preparation and/or blood products since birth.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 64 Days
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).